Stimulant medications may improve sleep in adults with ADHD, trial finds

For decades, clinicians have faced a paradox at the heart of attention deficit hyperactivity disorder treatment. The medications that sharpen focus during the day are stimulants, and stimulants are widely assumed to sabotage sleep at night. Now a randomized cross-over trial conducted at Geneva University Hospital suggests that this assumption may be wrong for many adults with ADHD. The study, published in BMC Psychiatry, found that stimulant medications reduced self-reported fatigue, improved subjective sleep quality, and made sleep objectively less fragmented, with no adverse sleep effects detected.

The research team, led by Kevin Mammeri and Laurence Bayer of the Service of Psychiatric Specialties at Geneva University Hospital, with Sebastien Weibel of Strasbourg University Hospital as co-first author, set out to address a gap that has long frustrated sleep researchers. Although stimulant medications such as methylphenidate and lisdexamfetamine are recommended as first-line treatment for ADHD symptoms in both children and adults, evidence about their impact on adult sleep has remained inconsistent, particularly when measured with objective tools rather than questionnaires alone.

To resolve that uncertainty, the investigators designed a study with unusual methodological rigor. They began with 36 adults with ADHD who had previously been identified as good responders to stimulant treatment. Each participant underwent clinical screening and an adaptation night in the sleep laboratory with full polysomnography, the gold-standard technique that records brain waves, eye movements, muscle tone, and heart rhythm throughout the night. From this pool, 15 participants were ultimately included and randomized in a cross-over trial, meaning each person completed both study conditions in randomly assigned order.

The cross-over design is critical to the study’s strength. Each participant spent one week under stimulant medication and one week without medication, with the order of the conditions randomized. After each week, they completed a night of polysomnography at the sleep center. Because every participant served as their own control, differences between the two conditions could be attributed to the medication itself rather than to stable individual differences in sleep architecture, age, or ADHD severity. Subjective measures were collected through questionnaires and sleep diaries, while objective sleep parameters were assessed using both actigraphy, a wrist-worn movement monitor, and polysomnography.

The subjective results pointed in a direction that contradicts clinical folklore. Compared with the no-medication condition, stimulant treatment reduced self-reported fatigue and improved how participants rated their own sleep quality. In other words, the very drugs often blamed for keeping patients awake were associated with feeling less tired during the day and sleeping better at night, at least as experienced by the patients themselves.

The objective data told a consistent story. Polysomnography revealed fewer transitions from deeper to lighter sleep stages under medication, a marker of more stable, less fragmented sleep. The researchers also documented fewer arousals during deep sleep, the slow-wave stage in which brief awakenings are particularly disruptive to restorative processes. Sleep fragmentation, the tendency of sleep to be broken by repeated micro-awakenings and stage shifts, is a well-established predictor of daytime impairment, and its reduction under treatment is a meaningful clinical finding.

Perhaps the most intriguing results concerned sleep microstructure. Stimulant medication increased the peak frequencies of both fast sleep spindles and slow oscillations. Sleep spindles are brief bursts of brain activity that occur during stage 2 sleep and are thought to support memory consolidation and the maintenance of sleep itself. Slow oscillations are the high-amplitude brain waves that characterize deep sleep and orchestrate the coordination of other sleep rhythms. The increase in fast spindle peak frequency was associated with increased dream experience, a relationship that links a specific pharmacological effect on brain rhythms to changes in conscious experience during sleep.

The authors propose that these findings reflect a beneficial and stabilizing effect of stimulant medications on the sleep-wake cycle in adults with ADHD, leading to better sleep. One hypothesis they raise is that the effect relates to a general mechanism of improved sleep-wake homeostasis: elevated daytime attention and consolidated sleep may reinforce each other, driving what the researchers describe as a virtuous therapeutic cycle. When attention is better regulated during the day, the pressure for restorative sleep may build and discharge more effectively, which in turn supports better attention the following day. Testing this mechanism, the authors note, would require further research.

For clinical practice, the implications are significant. The study’s conclusion is direct: stimulant medications may be administered to adult ADHD patients without causing adverse sleep outcomes. This challenges a common prescribing hesitation, in which clinicians worry that evening dosing or long-acting formulations will produce insomnia or degrade sleep quality. In this carefully controlled sample of good responders, the opposite pattern emerged, with medication associated with calmer, deeper, and less fragmented sleep.

The study does have boundaries that readers should keep in mind. The sample was small, with 15 participants completing the cross-over protocol, and all had previously been identified as good responders to stimulant treatment, which may limit generalizability to patients who tolerate these medications poorly or respond incompletely. The trial number was listed as not applicable, and the findings, while rigorous for their size, will need replication in larger and more diverse cohorts. The work was funded by Foundation TDAH-InSight, approved by the Swiss ethics committee under BASEC ID 2015-00168, and conducted with informed written consent from all patients, with the authors declaring no competing interests. Even with these caveats, the study offers a rare combination of subjective and objective evidence that, for many adults with ADHD, stimulant treatment and{

Subject of Research: Effects of stimulant medications on sleep in adults with ADHD

Article Title: The impact of psychostimulants on sleep in ADHD adults: a randomized cross-over trial

Article References: Mammeri, K., Weibel, S., Rüfenacht, E., Perrault, A. A., Pham, E., Cervena, K., Perogamvros, L., Schwartz, S., Perroud, N., & Bayer, L. (2026). The impact of psychostimulants on sleep in ADHD adults: a randomized cross-over trial. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08759-7

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08759-7

Keywords: ADHD, Sleep, Psychostimulants, Methylphenidate, Polysomnography, Sleep Spindles, impact, adults, randomized, cross-over, trial, scientific research